Log In
BCIQ
Print this Print this
 

TILs (LN-144) (formerly Contego)

  Manage Alerts
Collapse Summary General Information
Company Lion Biotechnologies Inc.
DescriptionAutologous T cell therapy that utilizes tumor infiltrating lymphocytes (TILs) derived from the patient's tumor
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$1.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/29/2013

Undisclosed

0

0

10/17/2011

Undisclosed

$1.2M

Undisclosed

Get a free BioCentury trial today